Bosnia and Herzegovina vs Greece: Share of E. coli infections resistant to cephalosporins
Bosnia and Herzegovina
26.8%
in 2022
Greece
24.0%
in 2022
Bosnia and Herzegovina rank
25th
Greece rank
27th
Share of E. coli infections resistant to cephalosporins over time
- Bosnia and Herzegovina
- Greece
How they compare
Bosnia and Herzegovina currently reports 26.8% against 24.0% in Greece, a difference of 2.8%.
That makes Bosnia and Herzegovina's figure about 1.1 times Greece's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was Bosnia and Herzegovina ahead.
Bosnia and Herzegovina ranks 25th and Greece ranks 27th of 46 countries.
Bosnia and Herzegovina has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bosnia and Herzegovina | Greece | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 21.8% | 19.8% | 2.0% | Bosnia and Herzegovina |
| 2020s | 26.4% | 23.5% | 2.9% | Bosnia and Herzegovina |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Bosnia and Herzegovina or Greece?
- Bosnia and Herzegovina, at 26.8% against 24.0% in Greece as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Bosnia and Herzegovina and Greece?
- 2.8%, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Greece?
- 6 years are reported by both, from 2017 to 2022.
- How do Bosnia and Herzegovina and Greece rank globally for share of e. coli infections resistant to cephalosporins?
- Bosnia and Herzegovina ranks 25th and Greece ranks 27th of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).